2018

(2018) An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Journal of Clinical Epidemiology, 99 . pp. 75-83. doi:10.1016/j.jclinepi.2018.02.018

2017

(2017) Body mass index and breast cancer survival : a Mendelian randomization analysis. International Journal of Epidemiology, 46 (6). pp. 1814-1822. doi:10.1093/ije/dyx131

2016

Dorling, L, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P. and Abraham, Jean E. (2016) The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7). e0158984. doi:10.1371/journal.pone.0158984

2015

Bartlett, J. M. S., McConkey, Christopher C., Munro, A. F., Desmedt, C., Dunn, Janet A., Larsimont, D., O'Malley, F. P., Cameron, D. A., Earl, H., Poole, Christopher J., Shepherd, L. E., Cardoso, F., Jensen, M., Caldas, C., Twelves, C. J., Rea, D. W., Ejlertsen, B., Di Leo, A. and Pritchard, K. I. (2015) Predicting anthracycline benefit : TOP2A and CEP17-not only but also. European Journal of Cancer Care, 33 (15). pp. 1680-1687. doi:10.1200/JCO.2013.54.7869

Bartlett, J. M. S., Stein, R. C., Bayani, J., Marshall, A. (Andrea)‏, Dunn, Janet A., Campbell, A. F., Cunningham, C., Sobol, M., Hall, P., Rooshenas, L., Morgan, A., Poole, Christopher J., Pinder, S. E., Cameron, D. A., Stallard, Nigel, Donovan, J., McCabe, C., Hughes-Davies, L. and Makris, A. (2015) Comparison of multiparameter tests in the UK OPTIMA-Prelim trial. Cancer Research, 75 (Supplement 9). P4-11-07 . doi:10.1158/1538-7445.SABCS14-P4-11-07

2013

Ali, Alaa M., Provenzano, Elena, Bartlett, John M. S., Abraham, Jean, Driver, Kristy, Munro, Alison F., Twelves, Chris, Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos and Pharoah, Paul D. (2013) Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, Volume 133 (Number 6). pp. 1470-1478. doi:10.1002/ijc.28150

(2013) Selecting breast cancer patients for chemotherapy : the opening of the UK OPTIMA trial. Clinical Oncology, Volume 25 (Number 2). pp. 109-116. doi:10.1016/j.clon.2012.10.005

2012

(2012) Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, Vol.107 (No.8). pp. 1257-1267. doi:10.1038/bjc.2012.370

Poole, Christopher J., Marshall, A. (Andrea)‏, Higgins, Helen B., Fletcher, J., Williams, S. J., Lo, N., Fernando, I. N., Osborne, R., Crawford, S. M., Rafii, S., Gill, S. and Dunn, Janet A. (2012) Neo-escape : Neoadjuvant extended sequential chemotherapy with adjuvant postoperative treatment for epithelial nonmucinous advanced inoperable peritoneal malignancy. Journal of Clinical Oncology, 30 (15). p. 1.

2011

Marshall, A. (Andrea), Dunn, Janet A., Fletcher, Julie, Higgins, Helen B. and Poole, Christopher (2011) The importance of planning for a seamless transition in an adaptive phase II randomised trial. Trials, Vol.12 (Suppl.1). A7. doi:10.1186/1745-6215-12-S1-A7

HER2 TOP2A Meta-Anal Study Group (Including:

). (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data. Lancet Oncology, Vol.12 (No.12). pp. 1134-1142. doi:10.1016/S1470-2045(11)70231-5

Campbell, H. E., Epstein, D., Bloomfield, D., Griffin, S., Manca, A., Yarnold, J., Bliss, J., Johnson, L., Earl, Helena M., Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Hopwood, P., Barrett-Lee, P., Ellis, P., Cameron, D., Harris, A. L., Gray, A. M. and Sculpher, Mark J. (2011) The cost-effectiveness of adjuvant chemotherapy for early breast cancer : a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer, Vol.47 (No.17). pp. 2517-2530. doi:10.1016/j.ejca.2011.06.019

Rustin, G., Reed, N., Jayson, G. C., Ledermann, J. A., Adams, M., Perren, T., Poole, Christopher, Lind, M., Persic, M., Essapen, S., Gore, M., Calvert, H., Stredder, C., Wagner, A., Giurescu, M. and Kaye, S. (2011) A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Annals of Oncology, Vol.22 (No.11). pp. 2411-2416. doi:10.1093/annonc/mdq780

Forster, Martin D., Dedes, Konstantin J., Sandhu, Shahneen, Frentzas, Sophia, Kristeleit, Rebecca, Ashworth, Alan, Poole, Christopher J., Weigelt, Britta, Kaye, Stan B. and Molife, L. Rhoda (2011) Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nature Reviews. Clinical Oncology, Volume 8 (Number 5). pp. 302-306. doi:10.1038/nrclinonc.2011.42

2010

Poole, Christopher J., Lisyanskaya, A., Rodenhuis, S., Kristensen, G., Lauraine, E. Pujade, Cantarini, M., Emeribe, U., Stuart, M. and Coquard, I. Ray (2010) A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin plus paclitaxel (C plus P) versus C plus P in patients (pts) wiht advanced platinum-sensitive epithelial ovarian cancer (eoc). In: 35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8-12 Oct 2010. Published in: Annals of Oncology, Volume 21 (Supplement 8). pp. 304-305. ISSN 0923-7534.

Bartlett, John M. S., Munro, A., O'Malley, Frances P., Earl, Helena M., Poole, Christopher J., Cardoso, Fatima, Twelves, Chris, Pritchard, Kathleen I., Rea, Daniel W. and Di Leo, A. (2010) Duplication of chromosome 17 CEP predicts for anthracycline benefit: evidence from an international meta-analysis of 4 adjuvant breast cancer trials for the HER2/TOP2A meta-analysis study group. In: European Breast Cancer Conference, Barcelona, Spain, March 24, 2010. Published in: European Journal of Cancer Supplements, Vol.8 (No.3). p. 121. ISSN 1359-6349.

Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D., Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M. and Poole, Christopher (2010) Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3). pp. 266-274. doi:10.1016/S1470-2045(10)70006-1

2009

Bartlett, J. M. S., Munro, A., Desmedt, Christine, Dunn, Janet A., Larsimont, D., O'Malley, F. P., Cameron, D. A., Earl, Helena M., Poole, Christopher J., Shepherd, Lois, Cardoso, Fatima, Caldas, Carlos, Twelves, Chris, Pritchard, K., Rea, D. W. and di Leo, A. (2009) Duplication of chromosome 17 CEP predicts for anthracycline benefit: a meta-analysis of 4 trials. In: 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, DEC 09-13, 2009. Published in: Cancer Research, Vol.69 (No.24 Suppl. 3). 716S-716S. ISSN 0008-5472. doi:10.1158/0008-5472.SABCS-09-4030

TACT Trial Management Grp, TACT Trialists (Including:

). (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) : an open-label, phase III, randomised controlled trial. Lancet, Vol.373 (No.9676). pp. 1681-1692. doi:10.1016/S0140-6736(09)60740-6

Bartlett, J. M. S., Munro, A., Dunn, Janet A., Hiller, Louise, Jordan, S., Twelves, Chris, Cameron, D. A., Thomas, J., Campbell, F., Rea, D. W., Provenzano, E., Pharoah, P., Caldas, Carlos, Earl, Helena M. and Poole, Christopher J. (2009) Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence from the UK NEA Tadjuvant breast cancer trial. In: 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008. Published in: Cancer Research, Vol.69 (No.2 Suppl. S). 74S-74S. ISSN 0008-5472. doi:10.1158/0008-5472.SABCS-45

2008

Behalf NEAT Investigators (Including: Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O'Reilly, S., Rea, D. W., Spooner, David A. and Poole, Christopher). (2008) NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life. British Journal of Cancer, Vol.99 (No.8). pp. 1226-1231. doi:10.1038/sj.bjc.6604674

tAnGo Trial Collaborators (Including: Wardley, A. M., Hiller, Louise, Howard, H. C., Dunn, Janet A., Bowman, A., Coleman, R. E., Fernando, I. N., Ritchie, D. M., Earl, Helena M. and Poole, Christopher J.). (2008) tAnGo : a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer : a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer, Vol.99 (No.4). pp. 597-603. doi:10.1038/sj.bjc.6604538

Kaye, Stan B., Poole, Christopher, Bidzinksi, M., Gianni, L., Gorbunova, V., Novikova, E., Strauss, A., McNally, V. A., Rossi, G. and Vergote, Ignace (2008) A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology, Vol.26 (No.15S). p. 5520.

Gray, R. G., Rea, Dean, Handley, K., Marshall, A. (Andrea), Pritchard, M. G., Perry, P., Earl, Helena M., Poole, Christopher J., Salman, A. and Lee, M. (2008) aTTom (adjuvant Tamoxifen--To offer more?) : randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer--Preliminary results. In: 2008 ASCO Annual Meeting, Chicago, Illinois, 30 May-3 Jun 2008. Published in: Journal of Clinical Oncology, Vol.26 (No.15S (May 20 Supplement)). p. 513. ISSN 0732-183X.

2006

(2006) Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. New England Journal of Medicine, Vol.355 (No.18). pp. 1851-1862. doi:10.1056/NEJMoa052084